

# Deborah J Stearns-Kurosawa

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8371734/publications.pdf>

Version: 2024-02-01

41  
papers

3,603  
citations

201385

27  
h-index

288905

40  
g-index

42  
all docs

42  
docs citations

42  
times ranked

3884  
citing authors

#	ARTICLE	IF	CITATIONS
1	Infection of Immunocompetent Conventional Mice with Shiga Toxin-Producing <i>E. coli</i> : The DSS+ÂSTEC Model. <i>Methods in Molecular Biology</i> , 2021, 2291, 353-364.	0.4	0
2	A computational solution to improve biomarker reproducibility during long-term projects. <i>PLoS ONE</i> , 2019, 14, e0209060.	1.1	7
3	Dextran Sulfate Sodium Colitis Facilitates Colonization with Shiga Toxin-Producing <i>Escherichia coli</i> : a Novel Murine Model for the Study of Shiga Toxicosis. <i>Infection and Immunity</i> , 2018, 86, .	1.0	5
4	Shiga Toxin Therapeutics: Beyond Neutralization. <i>Toxins</i> , 2017, 9, 291.	1.5	29
5	Pro-Coagulant Endothelial Dysfunction Results from EHEC Shiga Toxins and Host Damage-Associated Molecular Patterns. <i>Frontiers in Immunology</i> , 2015, 6, 155.	2.2	12
6	Shiga Toxin 2-Induced Endoplasmic Reticulum Stress Is Minimized by Activated Protein C but Does Not Correlate with Lethal Kidney Injury. <i>Toxins</i> , 2015, 7, 170-186.	1.5	11
7	Complement, thrombotic microangiopathy and disseminated intravascular coagulation. <i>Journal of Intensive Care</i> , 2014, 2, 65.	1.3	50
8	Distinct Renal Pathology and a Chemotactic Phenotype after Enterohemorrhagic <i>Escherichia coli</i> Shiga Toxins in Non-Human Primate Models of Hemolytic Uremic Syndrome. <i>American Journal of Pathology</i> , 2013, 182, 1227-1238.	1.9	35
9	Sepsis: Multiple Abnormalities, Heterogeneous Responses, and Evolving Understanding. <i>Physiological Reviews</i> , 2013, 93, 1247-1288.	13.1	324
10	Quiescent complement in nonhuman primates during <i>E. coli</i> Shiga toxin-induced hemolytic uremic syndrome and thrombotic microangiopathy. <i>Blood</i> , 2013, 122, 803-806.	0.6	20
11	Plasma Bacterial and Mitochondrial DNA Distinguish Bacterial Sepsis From Sterile Systemic Inflammatory Response Syndrome and Quantify Inflammatory Tissue Injury in Nonhuman Primates. <i>Shock</i> , 2013, 39, 55-62.	1.0	85
12	Impaired function of the Tie-2 receptor contributes to vascular leakage and lethality in anthrax. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 10024-10029.	3.3	50
13	Shiga Toxins and the Pathophysiology of Hemolytic Uremic Syndrome in Humans and Animals. <i>Toxins</i> , 2012, 4, 1261-1287.	1.5	131
14	The Pathogenesis of Sepsis. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2011, 6, 19-48.	9.6	479
15	Rescue from lethal Shiga toxin 2-induced renal failure with a cell-permeable peptide. <i>Pediatric Nephrology</i> , 2011, 26, 2031-2039.	0.9	41
16	Distinct Physiologic and Inflammatory Responses Elicited in Baboons after Challenge with Shiga Toxin Type 1 or 2 from Enterohemorrhagic <i>Escherichia coli</i> . <i>Infection and Immunity</i> , 2010, 78, 2497-2504.	1.0	55
17	PROC, PROCR and PROS1 polymorphisms, plasma anticoagulant phenotypes, and risk of cardiovascular disease and mortality in older adults: the Cardiovascular Health Study. <i>Journal of Thrombosis and Haemostasis</i> , 2008, 6, 1625-1632.	1.9	47
18	Soluble thrombomodulin: A sign of bad times*. <i>Critical Care Medicine</i> , 2008, 36, 985-987.	0.4	12

#	ARTICLE	IF	CITATIONS
19	A phase II trial of thalidomide in patients with refractory endometrial cancer and correlation with angiogenesis biomarkers: A Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2007, 105, 508-516.	0.6	90
20	A phase II trial of thalidomide in patients with refractory leiomyosarcoma of the uterus and correlation with biomarkers of angiogenesis: A gynecologic oncology group study. <i>Gynecologic Oncology</i> , 2007, 106, 596-603.	0.6	39
21	Sepsis and Pathophysiology of Anthrax in a Nonhuman Primate Model. <i>American Journal of Pathology</i> , 2006, 169, 433-444.	1.9	90
22	PROTEINASE 3 EXPRESSION ON NEUTROPHIL MEMBRANES FROM PATIENTS WITH INFECTIOUS DISEASE. <i>Shock</i> , 2006, 26, 128-133.	1.0	18
23	EPCR Ser219Gly: Elevated sEPCR, prothrombin F1+2, risk for coronary heart disease, and increased sEPCR shedding in vitro. <i>Atherosclerosis</i> , 2005, 183, 283-292.	0.4	56
24	Bimodal distribution of soluble endothelial protein C receptor levels in healthy populations. <i>Journal of Thrombosis and Haemostasis</i> , 2003, 1, 855-856.	1.9	20
25	Reduced Neutrophil CD10 Expression in Nonhuman Primates and Humans After In Vivo Challenge with <i>E. coli</i> or Lipopolysaccharide. <i>Shock</i> , 2003, 20, 130-137.	1.0	27
26	Plasma levels of endothelial protein C receptor respond to anticoagulant treatment. <i>Blood</i> , 2002, 99, 526-530.	0.6	60
27	Plasma levels of soluble endothelial cell protein C receptor in patients with Wegener's granulomatosis. <i>Clinical and Experimental Immunology</i> , 2002, 128, 187-194.	1.1	23
28	The endothelial cell protein C receptor aids in host defense against <i>Escherichia coli</i> sepsis. <i>Blood</i> , 2000, 95, 1680-1686.	0.6	302
29	The Soluble Endothelial Protein C Receptor Binds to Activated Neutrophils: Involvement of Proteinase-3 and CD11b/CD18. <i>Journal of Immunology</i> , 2000, 165, 4697-4703.	0.4	123
30	The endothelial cell protein C receptor aids in host defense against <i>Escherichia coli</i> sepsis. <i>Blood</i> , 2000, 95, 1680-6.	0.6	87
31	Endothelial Protein C Receptor. <i>Thrombosis and Haemostasis</i> , 1999, 82, 251-258.	1.8	107
32	Regulation and functions of the protein C anticoagulant pathway. <i>Haematologica</i> , 1999, 84, 363-8.	1.7	69
33	A Chimeric Protein C Containing the Prothrombin Gla Domain Exhibits Increased Anticoagulant Activity and Altered Phospholipid Specificity. <i>Journal of Biological Chemistry</i> , 1998, 273, 9031-9040.	1.6	43
34	Plasma levels of endothelial cell protein C receptor are elevated in patients with sepsis and systemic lupus erythematosus: lack of correlation with thrombomodulin suggests involvement of different pathological processes. <i>Blood</i> , 1998, 91, 725-7.	0.6	66
35	The Protein C Pathway: New Insights. <i>Thrombosis and Haemostasis</i> , 1997, 78, 070-074.	1.8	95
36	Identification of functional endothelial protein C receptor in human plasma.. <i>Journal of Clinical Investigation</i> , 1997, 100, 411-418.	3.9	147

#	ARTICLE	IF	CITATIONS
37	The protein C pathway: new insights. <i>Thrombosis and Haemostasis</i> , 1997, 78, 70-4.	1.8	19
38	The endothelial cell protein C receptor augments protein C activation by the thrombin-thrombomodulin complex.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1996, 93, 10212-10216.	3.3	512
39	The Endothelial Cell Protein C Receptor. <i>Journal of Biological Chemistry</i> , 1996, 271, 17499-17503.	1.6	77
40	The Endothelial Cell Protein C Receptor. <i>Journal of Biological Chemistry</i> , 1996, 271, 17491-17498.	1.6	123
41	The effect of calcium ionophore A23187 on tissue factor activity and mRNA in endothelial cells. <i>Thrombosis Research</i> , 1994, 74, 95-103.	0.8	17